Dimensional Fund Advisors
KLRS

Dimensional Fund Advisors’s Kalaris Therapeutics KLRS Stock Holding History

Dimensional Fund Advisors’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$65K Buy
+15,958
New +$82.9K ﹤0.01% 3177
2025
Q1 		– Sell
-3,033
Closed -$29.5K – 3363
2024
Q4 		$29.5K Hold
3,033
– – ﹤0.01% 3317
2024
Q3 		$56.3K Hold
3,033
– – ﹤0.01% 3289
2024
Q2 		$50.8K Hold
3,033
– – ﹤0.01% 3314
2024
Q1 		$52.7K Sell
3,033
-61
-2% -$995 ﹤0.01% 3331
2023
Q4 		$48.4K Sell
3,094
-1,860
-38% -$73.3K ﹤0.01% 3349
2023
Q3 		$245K Sell
4,954
-5,159
-51% -$352K ﹤0.01% 3185
2023
Q2 		$791K Sell
10,113
-2,954
-23% -$281K ﹤0.01% 2968
2023
Q1 		$1.18M Buy
+13,067
New +$1.66M ﹤0.01% 2867
2022
Q3 		$508K Sell
2,800
-1,161
-29% -$181K ﹤0.01% 3044
2022
Q2 		$356K Buy
3,961
+901
+29% +$94.5K ﹤0.01% 3143
2022
Q1 		$476K Buy
3,060
+927
+43% +$185K ﹤0.01% 3161
2021
Q4 		$635K Buy
+2,133
New +$990K ﹤0.01% 3118

Other funds holding KLRS

SB
Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors's KLRS Position: Q2 2026 in Review

Dimensional Fund Advisors opened a new position in Kalaris Therapeutics (KLRS) in Q2 2026: 15,958 shares worth $65K. The stake represents ﹤0.01% of the portfolio and ranks #3177 among its holdings. This is a return to the name: Dimensional Fund Advisors previously reported a position in KLRS as recently as Q4 2024.

Dimensional Fund Advisors first reported a position in KLRS in Q4 2021 and has held it in 13 quarters since. The position peaked at $1.18M in Q1 2023. 57 funds tracked by Wall St. Rank hold KLRS as of Q2 2026.

  • Dimensional Fund Advisors held 15,958 shares of Kalaris Therapeutics worth $65K as of Q2 2026.
  • Kalaris Therapeutics was a new Dimensional Fund Advisors position in Q2 2026.
  • Kalaris Therapeutics made up ﹤0.01% of Dimensional Fund Advisors's portfolio in Q2 2026, its #3177 holding.
  • Dimensional Fund Advisors first reported a position in Kalaris Therapeutics in Q4 2021 and has held it in 13 quarters since.
  • Dimensional Fund Advisors's Kalaris Therapeutics position peaked at $1.18M in Q1 2023.
  • 57 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q2 2026.

Based on Dimensional Fund Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.